| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | PD-L1 IHC 22C3 pharmDx |
| Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
| Applicant | Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Santa Clara, CA 95051 |
| PMA Number | P150013 |
| Supplement Number | S017 |
| Date Received | 06/14/2019 |
| Decision Date | 03/19/2020 |
| Product Code |
PLS |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Change Design/Components/Specifications/Material |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approved to migrate the PD-L1 IHC 22C3 pharmDx assay for NSCLC indication for use on the Dako Omnis automated staining system per approval letter. |
|
|